20 "Past Their Prime" Stocks to Dump From Your Portfolio in 2017

Share on StockTwits


Did you know the S&P 500 as we know it today does not look anything close to what it looked like 30 years ago? In 1987, IBM, Exxon, GE, Shell, AT&T, Merck, Du Pont, Philip Morris, Ford and GM had the largest market caps on the S&P 500. ExxonMobil is the only company on that list to remain in the top 10 in 2017. Even just 15 years ago, companies like Radio Shack, AOL, Yahoo and Blockbuster were an important part of the S&P 500. Now, these companies no longer exist as public companies.

As the years go by, some companies lose their luster and others rise to the top of the markets. We've already seen this in the last few decades with tech companies surpassing industrial and energy companies that once dominated the S&P 500. It's hard to know what the next mega trend will be that will knock Apple, Google and Amazon off the top rankings of the S&P 500, but we do know that companies won't stay on the S&P 500 forever.

We've identified 20 companies that are past their prime. They aren't at risk of a near-term delisting from the S&P 500, but they are showing negative earnings growth for the next several years. If you own any of these stocks, consider selling them now before they become the next Yahoo, Radio Shack, Blockbuster, AOL and are sold off for a fraction of their former value.

#1 - Euronav (NYSE:EURN)

Trailing Twelve Months EPS: $1.29
2017 EPS Estimate: ($0.06)
2018 EPS Estimate: ($0.18)

Current Price: $8.35
P/E Ratio: 119.3
Consensus Rating: Buy
Ratings Breakdown: 2 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $9.25 (10.8% Upside)

Euronav logoEuronav NV, together with its subsidiaries, owns, operates, and manages a fleet of vessels for the ocean transportation and storage of crude oil and petroleum products worldwide. The company operates through two segments, Tankers; and Floating Production, Storage, and Offloading Operations. As of April 4, 2017, it owned and operated a fleet of 55 double hulled vessels, including 31 very large crude carriers, 1 V-Plus vessel, 19 Suezmax vessels, and 2 floating, storage, and offloading vessels, as well as 2 Suezmax vessels under construction. The company was incorporated in 2003 and is headquartered in Antwerp, Belgium.

#2 - Oceaneering International (NYSE:OII)

Trailing Twelve Months EPS: ($0.19)
2017 EPS Estimate: ($0.09)
2018 EPS Estimate: ($0.40)

Current Price: $18.59
P/E Ratio: 642.0
Consensus Rating: Hold
Ratings Breakdown: 5 Buy Ratings, 12 Hold Ratings, 3 Sell Ratings.
Consensus Price Target: $24.84 (33.6% Upside)

Oceaneering International logoOceaneering International, Inc. is an oilfield provider of engineered services and products, primarily to the offshore oil and gas industry, with a focus on deepwater applications. The Company's business segments are contained within two businesses: services and products provided to the oil and gas industry (Oilfield) and all other services and products (Advanced Technologies). Its four business segments within the Oilfield business are Remotely Operated Vehicles (ROVs), Subsea Products, Subsea Projects and Asset Integrity. The services and products it provides to the oil and gas industry include remotely operated vehicles, specialty subsea hardware, engineering and project management, subsea intervention services, including manned diving, survey and positioning services and asset integrity and nondestructive testing services. The Company serves the defense, aerospace and commercial theme park industries.

#3 - Antero Resources (NYSE:AR)

Trailing Twelve Months EPS: ($1.14)
2017 EPS Estimate: ($0.12)
2018 EPS Estimate: ($0.28)

Current Price: $17.92
P/E Ratio: 97.6
Consensus Rating: Buy
Ratings Breakdown: 11 Buy Ratings, 11 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $27.33 (52.5% Upside)

Antero Resources logoAntero Resources Corporation is an oil and natural gas company. The Company is engaged in the exploration, development and acquisition of natural gas, natural gas liquids (NGLs) and oil properties located in the Appalachian Basin. The Company's segments include the exploration, development and production of natural gas, NGLs and oil; gathering and processing; water handling and treatment, and marketing of excess firm transportation capacity. The Company's subsidiary, Antero Midstream Partners LP (Antero Midstream) is a master limited partnership, which owns, operates and develops midstream energy infrastructure primarily to service its production and completion activity. Its exploration and development activities are supported by the natural gas gathering and compression assets of its subsidiary, Antero Midstream, as well as by third party gathering and compression arrangements. It also has access to additional low-pressure and high-pressure pipelines.

#4 - Hutchison China MediTech (NASDAQ:HCM)

2017 EPS Estimate: ($0.20)
2018 EPS Estimate: ($0.41)

Current Price: $31.11
Consensus Rating: Buy
Ratings Breakdown: 2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $32.00 (2.9% Upside)

Hutchison China MediTech logoHutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures markets and distributes prescription drugs and consumer health products in China.

#5 - Halozyme Therapeutics (NASDAQ:HALO)

Trailing Twelve Months EPS: ($0.68)
2017 EPS Estimate: $0.27
2018 EPS Estimate: ($0.71)

Current Price: $20.54
Consensus Rating: Hold
Ratings Breakdown: 3 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $18.00 (-12.4% Upside)

Halozyme Therapeutics logoHalozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex recombinant. The Company's development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

#6 - Transocean (NYSE:RIG)

Trailing Twelve Months EPS: ($7.11)
2017 EPS Estimate: ($0.34)
2018 EPS Estimate: ($0.80)

Current Price: $9.51
P/E Ratio: 12.7
Consensus Rating: Hold
Ratings Breakdown: 13 Buy Ratings, 10 Hold Ratings, 9 Sell Ratings.
Consensus Price Target: $12.15 (27.8% Upside)

Transocean logoTransocean Ltd. is an international provider of offshore contract drilling services for oil and gas wells. The Company's primary business is to contract its drilling rigs, related equipment and work crews on a dayrate basis to drill oil and gas wells. As of February 9, 2017, it owned or had partial ownership interests in and operated 56 mobile offshore drilling units. As of February 9, 2017, its fleet consisted of 30 floaters, seven harsh environment floaters, three deepwater floaters, six midwater floaters and 10 high-specification jackups. As February 9, 2017, it also had four ultra-deepwater drillships and five high-specification jackups under construction or under contract to be constructed. Its contract drilling services operations are spread across oil and gas exploration and development areas throughout the world. The Company's drilling fleet can be characterized as floaters, including drillships and semisubmersibles, and jackups.

#7 - Five9 (NASDAQ:FIVN)

Trailing Twelve Months EPS: ($0.15)
2017 EPS Estimate: ($0.18)
2018 EPS Estimate: ($0.20)

Current Price: $23.26
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $26.17 (12.5% Upside)

Five9 logoFive9 Inc. (Five9) is a provider of cloud software for contact centers. The Company's purpose-built Virtual Contact Center (VCC) cloud platform delivers a suite of applications that enable the breadth of contact center-related customer service, sales and marketing functions. The Company's solution, which consists of its VCC cloud platform and applications, allows simultaneous management and optimization of customer interactions across voice, chat, e-mail, Web, social media and mobile channels, either directly or through its application programming interfaces (APIs). The Company's VCC cloud platform matches each customer interaction with an appropriate agent resource and delivers relevant customer data to the agent in real-time through integrations with adjacent enterprise applications, such as customer relationship management (CRM) software, to optimize the customer experience and agent productivity.

#8 - Rowan Companies (NYSE:RDC)

Trailing Twelve Months EPS: ($0.52)
2017 EPS Estimate: ($0.65)
2018 EPS Estimate: ($2.54)

Current Price: $13.55
Consensus Rating: Hold
Ratings Breakdown: 6 Buy Ratings, 11 Hold Ratings, 2 Sell Ratings.
Consensus Price Target: $16.43 (21.2% Upside)

Rowan Companies logoRowan Companies plc is a provider of offshore contract drilling services to the international oil and gas industry. The Company operates through two segments: deepwater and jack-ups. Its deepwater segment consists of drillship operations. As of December 31, 2016, the Company's fleet consisted of 29 mobile offshore drilling units, including 25 self-elevating jack-up rigs and four ultra-deepwater drillships. The Company's fleet operates across the world, including the United States Gulf of Mexico (US GOM), the United Kingdom and Norwegian sectors of the North Sea, the Middle East and Trinidad. As of February 14, 2017, the Company's drilling fleet consisted of four ultra-deepwater drillships; 19 high-specification cantilever jack-up rigs, and six premium cantilever jack-up rigs. Its jack-ups are capable of drilling wells to maximum depths ranging from 25,000 to 40,000 feet and in maximum water depths ranging from 300 to 550 feet, depending on rig size, location and outfitting.

#9 - Alteryx (NYSE:AYX)

Trailing Twelve Months EPS: ($0.56)
2017 EPS Estimate: ($0.33)
2018 EPS Estimate: ($0.41)

Current Price: $27.83
Consensus Rating: Buy
Ratings Breakdown: 8 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $21.67 (-22.1% Upside)

Alteryx logoAlteryx, Inc. is a United States-based provider of self-service data analytics software. The Company offers various products, such as Alteryx Designer, Alteryx Server and Alteryx Analytics Gallery. Alteryx Designer is a repeatable workflow for self-service data analytics. Alteryx Designer allows data analysts by combining data preparation, data blending, and analytics-predictive, statistical and spatial-using the same user interface. Alteryx Server is a scalable platform to deploy and share analytics. Alteryx Server accelerates time to analytical insight, and allows analysts and business users across organization to make data-driven decisions. Alteryx Analytics Gallery is an analytics cloud platform to recognize that business decision makers expect their business applications to be as engaging as the applications they use at home. Its solutions include analytic, departmental and industry. Its analytic solutions connect business analysts and decision makers to data.

#10 - Ensco (NYSE:ESV)

Trailing Twelve Months EPS: ($0.19)
2017 EPS Estimate: ($0.53)
2018 EPS Estimate: ($0.90)

Current Price: $5.26
Consensus Rating: Hold
Ratings Breakdown: 9 Buy Ratings, 7 Hold Ratings, 3 Sell Ratings.
Consensus Price Target: $8.32 (58.2% Upside)

Ensco logoEnsco plc is an offshore contract drilling company. The Company provides offshore contract drilling services to the international oil and gas industry. Its segments include Floaters, Jackups and Other. The Floaters segment includes its drillships and semisubmersible rigs, and provides contract drilling. Other consists of management services on rigs owned by third parties. The Floaters and the Jackups segments provide contract drilling. It owned and operated an offshore drilling rig fleet of 57 rigs, including two rigs under construction, with drilling operations around the world, as of December 31, 2016. As of December 31, 2016, its rig fleet included eight drill ships, 10 dynamically positioned semisubmersible rigs, three moored semisubmersible rigs and 38 jackup rigs. As of December 31, 2016, of its 59 rigs, 25 were located in the Middle East, Africa and Asia Pacific, 16 were located in North and South America (including Brazil) and 18 were located in Europe and the Mediterranean.

#11 - Appian (NASDAQ:APPN)

2017 EPS Estimate: ($0.39)
2018 EPS Estimate: ($0.47)

Current Price: $20.46
Consensus Rating: Hold
Ratings Breakdown: 2 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $21.50 (5.1% Upside)

Appian logoAppian Corporation provides a low-code software development platform as a service that enables organizations to develop applications. Through Company’s platform, organizations can design, build and implement, enterprise-grade custom applications. Decision makers can reimagine their products, services, processes and customer interactions. The Company’s platform automates the creation of forms, data flows, records, reports and other software elements. The Company’s SAIL technology allows developers to create an application once and deploy it everywhere. The Company’s products include business process management (BPM) software, case management, mobile application development and platform as a service. The Company provides its services to a range of industries including energy, insurance, health payers and providers, manufacturing, public sector, retail and transportation.

#12 - Imperva (NASDAQ:IMPV)

Trailing Twelve Months EPS: $0.27
2017 EPS Estimate: ($0.52)
2018 EPS Estimate: ($0.82)

Current Price: $40.45
Consensus Rating: Hold
Ratings Breakdown: 8 Buy Ratings, 6 Hold Ratings, 2 Sell Ratings.
Consensus Price Target: $51.33 (26.9% Upside)

Imperva logoImperva, Inc. provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company's products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services. Its Imperva SecureSphere provides database, file and Web application security across various physical and virtual systems in data centers, including in private, public and hybrid cloud computing environments. Its Imperva Incapsula product line provides cloud-based Website security, denial of service protection and performance solutions. Its Imperva Camouflage creates realistic, functional data for development, testing, and training by disguising sensitive information, while maintaining the characteristics of the original data.

#13 - TherapeuticsMD (NASDAQ:TXMD)

Trailing Twelve Months EPS: ($0.39)
2017 EPS Estimate: ($0.37)
2018 EPS Estimate: ($0.40)

Current Price: $6.48
Consensus Rating: Buy
Ratings Breakdown: 8 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $15.00 (131.5% Upside)

TherapeuticsMD logoTherapeuticsMD, Inc. is a women's healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.

#14 - Overstock.com (NASDAQ:OSTK)

Trailing Twelve Months EPS: ($0.43)
2017 EPS Estimate: ($0.47)
2018 EPS Estimate: ($0.51)

Current Price: $61.50
Consensus Rating: Buy
Ratings Breakdown: 2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $56.00 (-8.9% Upside)

Overstock.com logoOverstock.com, Inc. is an online retailer and incubator of blockchain technology. Through its online retail business, the Company offers a range of price-competitive brand name, non-brand name and closeout products, including furniture, home decor, bedding and bath, housewares, jewelry and watches, apparel and designer accessories, health and beauty products, electronics and computers, and sporting goods. It operates Retail and Medici businesses. Its Retail business consists of its Direct and Partner segments. Its Other segment consists of Medici. The Company also sells various books, magazines, compact discs (CDs), digital versatile discs (DVDs) and video games. The Company sells these products and services through its Internet Websites located at www.overstock.com, www.o.co and www.o.biz. The Company's other offerings include Worldstock Fair Trade, Main Street Revolution, Farmers Market, Pet Adoptions, Insurance and Supplier Oasis.

#15 - Alkermes (NASDAQ:ALKS)

Trailing Twelve Months EPS: ($1.11)
2017 EPS Estimate: ($0.59)
2018 EPS Estimate: ($0.76)

Current Price: $51.56
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $64.50 (25.1% Upside)

Alkermes logoAlkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

#16 - Nektar Therapeutics (NASDAQ:NKTR)

Trailing Twelve Months EPS: ($0.71)
2017 EPS Estimate: ($0.75)
2018 EPS Estimate: ($1.21)

Current Price: $55.05
Consensus Rating: Buy
Ratings Breakdown: 12 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $36.64 (-33.4% Upside)

Nektar Therapeutics logoNektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, Pain-NKTR-181 and Oncology-ONZEALD. It is developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells.

#17 - 2U (NASDAQ:TWOU)

Trailing Twelve Months EPS: ($0.67)
2017 EPS Estimate: ($0.60)
2018 EPS Estimate: ($0.77)

Current Price: $63.84
Consensus Rating: Buy
Ratings Breakdown: 10 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $71.40 (11.8% Upside)

2U logo2U, Inc. is a provider of an integrated solution consisting of cloud-based software-as-a-service (SaaS) combined with technology-enabled services (together, the Platform) that allows colleges and universities to deliver online degree programs. The Company's SaaS technology consists of a learning environment (Online Campus), which acts as the hub for all student and faculty academic and social interaction, and a suite of integrated applications, which the Company uses to launch, operate and support the Company's clients' programs. The Company also provides a suite of technology-enabled services optimized with data analysis and machine learning techniques that support the complete lifecycle of a higher education program, including attracting students, advising students through the admissions application process, providing technical, success coaching and other support, facilitating accessibility to individuals with disabilities, and facilitating in-program field placements.

#18 - Beigene (NASDAQ:BGNE)

Trailing Twelve Months EPS: ($1.30)
2017 EPS Estimate: ($2.04)
2018 EPS Estimate: ($7.56)

Current Price: $93.87
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $93.00 (-0.9% Upside)

Beigene logoBeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016. BGB-3111, BGB-290 and BGB-283 are its molecularly targeted agents and is its immuno-oncology agent. BGB-3111 is a potent and highly selective small molecule inhibitor of Bruton's tyrosine kinase (BTK). BGB-283 is a molecule inhibitor of both the monomer and dimer forms of the RAF kinase. BGB-290 is a molecularly targeted, orally available, potent and highly selective inhibitor of the poly ADP ribose polymerase (PARP) family members. BGB-A317 is an investigational humanized monoclonal antibody against the immune checkpoint receptor, PD-1.

#19 - Mulesoft (NYSE:MULE)

2017 EPS Estimate: ($0.64)
2018 EPS Estimate: ($0.72)

Current Price: $23.32
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $27.63 (18.5% Upside)

Mulesoft logoMuleSoft, Inc. is engaged in providing a software platform that connects a range of technologies. The Company enables organizations to manage and secure the flow of data between all systems in the enterprise. The Company offers organizations to create agile infrastructures. The Company has developed Anypoint Platform. The Company's customers use its Anypoint Platform to connect their applications, data, and devices into an application network where systems are pluggable instead of glued together with custom integration code. The application network enables a self-serve infrastructure through discoverable building blocks, or nodes, that can be used and reused to rapidly compose applications. With an application network built with Anypoint Platform, organizations can transform into composable enterprises.

#20 - Seattle Genetics (NASDAQ:SGEN)

Trailing Twelve Months EPS: ($0.86)
2017 EPS Estimate: ($0.93)
2018 EPS Estimate: ($1.33)

Current Price: $51.82
Consensus Rating: Hold
Ratings Breakdown: 9 Buy Ratings, 11 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $63.20 (22.0% Upside)

Seattle Genetics logoSeattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company's pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.







More on MarketBeat
15 Technology Stocks that Analysts Love15 Technology Stocks that Analysts Love
7 Best Stocks to Own Right Now7 Best Stocks to Own Right Now
Analysts Hate These 12 StocksAnalysts Hate These 12 Stocks
15 REITS Analysts Can15 REITS Analysts Can't Stop Recommending
15 Energy Stocks Analysts Love the Most15 Energy Stocks Analysts Love the Most
The 15 Best Growth Stocks You Can Buy Right NowThe 15 Best Growth Stocks You Can Buy Right Now
12 Marijuana Stocks to Buy Now12 Marijuana Stocks to Buy Now


Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.